XML 40 R30.htm IDEA: XBRL DOCUMENT v3.19.1
Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following table summarizes our intangible assets, net (in millions):
 
 
March 31, 2019
 
December 31, 2018
 
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
Finite-lived assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intangible asset - sofosbuvir
 
$
10,720

 
$
(3,729
)
 
$

 
$
6,991

 
$
10,720

 
$
(3,554
)
 
$

 
$
7,166

Intangible asset - axicabtagene ciloleucel (DLBCL)
 
6,200

 
(502
)
 

 
5,698

 
6,200

 
(416
)
 

 
5,784

Intangible asset - Ranexa
 
688

 
(688
)
 

 

 
688

 
(678
)
 

 
10

Other
 
1,098

 
(387
)
 
(4
)
 
707

 
1,096

 
(359
)
 
(3
)
 
734

Total finite-lived assets
 
18,706

 
(5,306
)
 
(4
)
 
13,396

 
18,704

 
(5,007
)
 
(3
)
 
13,694

Indefinite-lived assets - In Process Research & Development
 
2,047

 

 
(5
)
 
2,042

 
2,047

 

 
(3
)
 
2,044

Total intangible assets
 
$
20,753

 
$
(5,306
)
 
$
(9
)
 
$
15,438

 
$
20,751

 
$
(5,007
)
 
$
(6
)
 
$
15,738

Schedule of Indefinite-Lived Intangible Assets
The following table summarizes our intangible assets, net (in millions):
 
 
March 31, 2019
 
December 31, 2018
 
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
Finite-lived assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intangible asset - sofosbuvir
 
$
10,720

 
$
(3,729
)
 
$

 
$
6,991

 
$
10,720

 
$
(3,554
)
 
$

 
$
7,166

Intangible asset - axicabtagene ciloleucel (DLBCL)
 
6,200

 
(502
)
 

 
5,698

 
6,200

 
(416
)
 

 
5,784

Intangible asset - Ranexa
 
688

 
(688
)
 

 

 
688

 
(678
)
 

 
10

Other
 
1,098

 
(387
)
 
(4
)
 
707

 
1,096

 
(359
)
 
(3
)
 
734

Total finite-lived assets
 
18,706

 
(5,306
)
 
(4
)
 
13,396

 
18,704

 
(5,007
)
 
(3
)
 
13,694

Indefinite-lived assets - In Process Research & Development
 
2,047

 

 
(5
)
 
2,042

 
2,047

 

 
(3
)
 
2,044

Total intangible assets
 
$
20,753

 
$
(5,306
)
 
$
(9
)
 
$
15,438

 
$
20,751

 
$
(5,007
)
 
$
(6
)
 
$
15,738

Schedule of Estimated Future Amortization Expense
The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March 31, 2019 (in millions):
Fiscal Year
 
Amount
2019 (remaining nine months)
 
$
851

2020
 
1,125

2021
 
1,125

2022
 
1,125

2023
 
1,125

Thereafter
 
8,045

Total
 
$
13,396